Patents by Inventor Richard J. Gregory
Richard J. Gregory has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090088398Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective.Type: ApplicationFiled: May 27, 2008Publication date: April 2, 2009Applicant: Canji, Inc.Inventors: Richard J. Gregory, Ken N. Wills, Daniel C. Maneval
-
Publication number: 20090082289Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention- can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).Type: ApplicationFiled: May 2, 2007Publication date: March 26, 2009Applicant: Canji, Inc.Inventors: Richard J. Gregory, Ken N. Wills, Daniel C. Maneval
-
Publication number: 20080299083Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).Type: ApplicationFiled: June 14, 2007Publication date: December 4, 2008Applicant: Canji, Inc.Inventors: Richard J. Gregory, Ken N. Wills, Daniel C. Maneval
-
Publication number: 20080182807Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).Type: ApplicationFiled: November 20, 2006Publication date: July 31, 2008Applicant: Canji, Inc.Inventors: Richard J. Gregory, Ken N. Wills, Daniel C. Maneval
-
Publication number: 20080175818Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).Type: ApplicationFiled: April 25, 2007Publication date: July 24, 2008Applicant: Canji, Inc.Inventors: Richard J. Gregory, Ken N. Wills, Daniel C. Maneval
-
Patent number: 7105156Abstract: Disclosed are methods of controlling cell cycle progression by introducing into a cell to be controlled a composition selected from the group consisting of p56RB protein, a fragment of the p56RB protein, and the gene encoding p56RB protein to alter the cell cycle progression while maintaining the viability of the cell. The p56RB protein has been found to have the unexpected and surprising characteristic of being soluble in low concentrations of glycerol, thereby enhancing its value in pharmaceutical applications and the gene encoding p56RB when delivered to the hyperproliferating cell inhibits cellular proliferation.Type: GrantFiled: June 7, 1995Date of Patent: September 12, 2006Assignees: The Regents of the University of California, Canji, Inc.Inventors: Wen-Hwa Lee, H. Michael Shepard, Richard J. Gregory, Ken N. Wills, Daniel C. Maneval, Eva Lee, David Goodrich, Nan-Ping Wang
-
Patent number: 7053062Abstract: The present invention provides recombinant nucleic acid molecules encoding a chimeric transactivator protein including a DNA binding domain of a DNA binding protein and a protein domain capable of transcriptional activation. The present invention also provides recombinant viral and non-viral vectors that are able to infect and/or transfect and sustain expression of a biologically active chimeric transactivator proteins in mammalian cells. Also provided are host cell lines and non-human transgenic animals capable of expressing biologically active chimeric transactivator proteins. In another aspect, compositions and methods for treating or preventing ischemic damage associated with hypoxia-related disorders are provided.Type: GrantFiled: July 3, 2002Date of Patent: May 30, 2006Assignee: Genzyme CorporationInventors: Richard J. Gregory, Karen Vincent
-
Patent number: 7041284Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine dinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective.Type: GrantFiled: October 28, 1997Date of Patent: May 9, 2006Assignee: Canji, Inc.Inventors: Richard J. Gregory, Ken N. Wills, Daniel C. Maneval
-
Patent number: 6989268Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with thymidine kinase metabolite in order to be effective).Type: GrantFiled: May 19, 2003Date of Patent: January 24, 2006Assignee: Canji, Inc.Inventors: Richard J. Gregory, Ken N. Wills, Daniel C. Maneval
-
Patent number: 6902731Abstract: Fusions of the transcription factor E2F and the retinoblastoma protein RB are provided, along with methods of treatment of hyperproliferative diseases.Type: GrantFiled: May 19, 1999Date of Patent: June 7, 2005Assignee: Canji, Inc.Inventors: Douglas Antelman, Richard J. Gregory, Kenneth N. Wills
-
Publication number: 20040266006Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention.Type: ApplicationFiled: January 27, 2004Publication date: December 30, 2004Applicant: Canji, Inc.Inventors: Richard J. Gregory, Ken N. Wills, Daniel C. Maneval
-
Publication number: 20040143104Abstract: Compositions, expression vectors and host cells comprising nucleic acid which encodes a precursor glucagon-like peptide 1 (GLP-1) comprising mammalian GLP-1 linked to a heterologous signal sequence are encompassed by the present invention. The invention also relates to a method of promoting insulin production in an individual comprising administering to the individual an effective amount of a nucleic acid encoding a precursor GLP-1. The present invention also relates to a method of treating an individual having a blood sugar defect (e.g., type I or type II diabetes), comprising administering to the individual an effective amount of a nucleic acid encoding the precursor GLP-1.Type: ApplicationFiled: November 17, 2003Publication date: July 22, 2004Inventors: Samuel C. Wadsworth, Donna Armentano, Richard J. Gregory, Geoffrey Parsons
-
Publication number: 20040087027Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention.Type: ApplicationFiled: June 23, 2003Publication date: May 6, 2004Applicant: Canji, Inc.Inventors: Richard J. Gregory, Ken N. Wills, Daniel C. Maneval
-
Publication number: 20040038404Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention.Type: ApplicationFiled: May 19, 2003Publication date: February 26, 2004Applicant: Canji, Inc.Inventors: Richard J. Gregory, Ken N. Wills, Daniel C. Maneval
-
Publication number: 20040002468Abstract: Compositions, expression vectors and host cells comprising nucleic acid which encodes a precursor glucagon-like peptide 1 (GLP-1) comprising mammalian GLP-1 linked to a heterologous signal sequence are encompassed by the present invention. The invention also relates to a method of promoting insulin production in an individual comprising administering to the individual an effective amount of a nucleic acid encoding a precursor GLP-1. The present invention also relates to a method of treating an individual having a blood sugar defect (e.g., type I or type II diabetes), comprising administering to the individual an effective amount of a nucleic acid encoding the precursor GLP-1.Type: ApplicationFiled: August 7, 2002Publication date: January 1, 2004Applicant: Genzyme CorporationInventors: Samuel C. Wadsworth, Donna Armentano, Richard J. Gregory, Geoffrey Parsons
-
Publication number: 20030147854Abstract: Gene Therapy vectors, which are especially useful for cystic fibrosis, and methods for using the vectors are disclosed.Type: ApplicationFiled: June 3, 2002Publication date: August 7, 2003Inventors: Richard J. Gregory, Donna Armentano, Larry A. Couture, Alan E. Smith
-
Publication number: 20030026789Abstract: This invention provides a method of treating cancer by administering a replication competent adenoviral vector comprising a therapeutic gene and a disease specific gene regulatory region operationally linked to at least one replication gene. The replication competent targeted adenoviral vector preferentially replicates in the tumor cells following activation of the tumor specific gene regulatory region thereby amplifying the effect of the therapeutic gene carried by the replication competent adenoviral vector. This invention enables for the first time the targeting of a therapeutic gene for treating cancer using small amounts of viral vectors which selectively replicate to deliver therapeutic dosages of the therapeutic gene.Type: ApplicationFiled: May 3, 1995Publication date: February 6, 2003Inventors: RICHARD J. GREGORY, WHEI-MEI HUANG
-
Publication number: 20030018007Abstract: The present invention provides recombinant nucleic acid molecules encoding a chimeric transactivator protein including a DNA binding domain of a DNA binding protein and a protein domain capable of transcriptional activation. The present invention also provides recombinant viral and non-viral vectors that are able to infect and/or transfect and sustain expression of a biologically active chimeric transactivator proteins in mammalian cells. Also provided are host cell lines and non-human transgenic animals capable of expressing biologically active chimeric transactivator proteins. In another aspect, compositions and methods for treating or preventing ischemic damage associated with hypoxia-related disorders are provided.Type: ApplicationFiled: July 3, 2002Publication date: January 23, 2003Applicant: Genzyme CorporationInventors: Richard J. Gregory, Karen Vincent
-
Patent number: 6485720Abstract: The present invention relates to transgene expression systems, related compositions comprising the transgene expression systems, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA encoding a transgene which codes for a desired product operably linked to expression control sequence, and at least a portion of the adenovirus E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E4ORF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or “E4 cassette”) includes E4ORF3 and at least one other portion selected from E4ORF4, E4ORF6/7 and E4ORF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell.Type: GrantFiled: August 8, 2001Date of Patent: November 26, 2002Assignee: Genzyme CorporationInventors: Johanne Kaplan, Donna Armentano, Richard J. Gregory
-
Publication number: 20020164782Abstract: Gene Therapy vectors, which are especially useful for cystic fibrosis, and methods for using the vectors are disclosed.Type: ApplicationFiled: May 11, 2000Publication date: November 7, 2002Inventors: Richard J. Gregory, Donna Armentano, Larry A. Couture, Alan E. Smith